Status:
UNKNOWN
Lifestyle Intervention in Fatty Liver (NAFLD)
Lead Sponsor:
University of Bari
Collaborating Sponsors:
European Commission
Conditions:
Non-Alcoholic Fatty Liver Disease
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Non-Alcoholic Fatty Liver Disease (NAFLD), including its more pathologic consequence, non-alcoholic steatohepatitis (NASH), is believed to be the most common chronic liver disease worldwide, affecting...
Detailed Description
Background Non-Alcoholic Fatty Liver Disease (NAFLD), including its more pathologic consequence, non-alcoholic steatohepatitis (NASH), is believed to be the most common chronic liver disease worldwid...
Eligibility Criteria
Inclusion
- Patients able to provide informed consent
- Certified diagnosis of NAFLD/NASH
- Body mass index between 25-40 Kg/m2
- Biohumoral alterations of lipidic and/or glucidic and/or liver metabolism
Exclusion
- Refusal to sign the informed consent
- Diagnosis of organic diseases including neoplastic, severe cardiovascular diseases, renal insufficiency, psychiatric disorders
- Significant alcohol consumption (\> 1 standard drink per day),
- Inability to walk 2 blocks or a quarter of a mile without stopping
- Engagement in an active weight loss program or taking weight loss medication
- Substance abuse
- Medication able to affect gastrointestinal tract and to interfere with symptoms
- Pregnancy
- Presence of diseases with a prognosis of less than 12 months
Key Trial Info
Start Date :
July 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03354247
Start Date
July 1 2017
End Date
December 31 2020
Last Update
January 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Biomedical Sciences Human Oncology - Clinica Medica "A. Murri"
Bari, BA, Italy, 70124